EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (9)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2021
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Annals of Oncology, Vol. 32, Núm. 2, pp. 208-217
-
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
Therapeutic Advances in Medical Oncology, Vol. 13
-
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 2005-2015
2020
-
Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial
Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197
2019
-
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
New England Journal of Medicine, Vol. 380, Núm. 20, pp. 1929-1940
2018
2017
-
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712
2016
-
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Annals of Oncology, Vol. 27, pp. vi98